Cell Therapeutics (CTIC) plummets 21% premarket following the pricing of its offering of 60K...


Cell Therapeutics (CTIC) plummets 21% premarket following the pricing of its offering of 60K shares of convertible preferred stock. Each share is convertible into about 714 shares of common  stock at a price of $1.40, making a total of approximately 42.9M shares. The current outstanding float is 52.25M shares. (PR)

From other sites
Comments (1)
  • Akber
    , contributor
    Comments (63) | Send Message
     
    This company is not for investors. They will issue more stocks and when share price goes under $1.00 you will get get a Reverse stock split. They have been doing this for many years. In last three years i think they have done more than three times. They just want to pay more to employees and don't care about shareholders. This will be good for SHORTS
    5 Oct 2012, 07:48 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs